With New Strategy, Alnylam Again Shuffles Its Pipeline

"As part of our … strategy, we have made portfolio decisions to focus our investments in our highest-value activities and on programs with exciting potential for addressing major unmet medical needs," Alnylam President and COO Barry Greene said in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.